Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase)